平田　賢郎 （ ヒラタ　ケンロウ ）

Hirata, Kenro

写真a

所属（所属キャンパス）

医学部 腫瘍センター （ 信濃町 ）

職名

専任講師
Scopus 論文情報  
総論文数: 76 総引用数: 1805 h-index: 24

Click to view the Scopus page. The data was downloaded from Scopus API inSeptember 06, 2026, via http://api.elsevier.com and http://www.scopus.com .

このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 2001年04月
    -
    2007年03月

    慶應義塾大学, 医学部

    大学

  • 2009年04月
    -
    2013年03月

    慶應義塾大学, 医学研究科

    大学院, 博士

このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 博士（医学）, 慶應義塾大学, 課程, 2014年02月

このページの先頭へ▲

免許・資格 【 表示 ／ 非表示 】

  • 日本内科学会　総合内科専門医, 2019年

  • 日本臨床腫瘍学会　がん薬物療法専門医

  • 日本がん治療認定医機構　がん治療認定医

  • 日本ヘリコバクター学会　H. pylori感染症認定医

  • 日本肝臓学会　肝臓専門医

全件表示 >>

このページの先頭へ▲
 

研究分野 【 表示 ／ 非表示 】

  • ライフサイエンス / 消化器内科学

このページの先頭へ▲

研究キーワード 【 表示 ／ 非表示 】

  • 消化器系悪性腫瘍

  • 胃癌

  • 食道癌

このページの先頭へ▲
 

論文 【 表示 ／ 非表示 】

  • Appetite, coping strategies, and morale in older adults with advanced gastrointestinal cancer: a longitudinal observational study

    Yagasaki K., Arahata T., Ishida N., Hirata K., Funato M., Hamamoto Y.

    BMC Geriatrics 26 （ 1 ）  2026年12月

    　概要を見る

    Background: Older adults with advanced gastrointestinal cancer face diverse physical challenges associated with the disease, treatments, and aging. Maintaining morale is crucial for these patients, as it enables them to sustain psychological well-being and a sense of fulfillment. We aimed to assess the relationships between appetite, coping strategies, and changes in morale after three months of follow-up in older adults with advanced gastrointestinal cancer. Methods: A three-month longitudinal observational study was conducted among 79 older adults (aged 70 and over) with advanced gastrointestinal cancer receiving chemotherapy as outpatients at a hospital in Japan between 2022 and 2024. We assessed morale using the Philadelphia Geriatric Center Morale Scale, appetite using the Simplified Nutritional Appetite Questionnaire, coping strategies using the Brief Coping Orientation to Problems Experienced Inventory, frailty using the Geriatric 8 scale, and symptoms using the MD Anderson Symptom Inventory. A linear mixed-effects model was used to estimate the difference in change in morale from baseline to three months later between high- and low-appetite groups. Results: Data from 66 participants who completed the follow-up were analyzed. The participants (mean age = 76.8 years) had a mean nutritional appetite score of 14.3, morale score of 12.0, and frailty score of 11.7. Acceptance was the most frequently used coping strategy. At three months from baseline, morale was lower in the low-appetite group than in the high-appetite group. While the change in morale over three months did not differ significantly between the two appetite groups, the use of substances as a coping strategy was significantly associated with lower morale after three months (p = 0.01). Conclusions: While low baseline appetite was associated with lower morale, it was not significantly associated with changes in morale over three months. Instead, reliance on substance use as a coping strategy appeared more important. Therefore, monitoring substance use may be useful for identifying patients who need greater psychological support. Additionally, considering support methods that enable older adults to enjoy eating aligned with their values might be beneficial. These results serve as a foundation for future research aimed at understanding and supporting the morale of older adults with gastrointestinal cancer.

  • Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)

    Kito Y., Yamazaki K., Shoji H., Yamada T., Tsushima T., Mitani S., Shiraishi K., Yasui H., Hara H., Hirata K., Esaki T., Shinohara Y., Tsuzuki T., Kajiura S., Masuishi T., Izawa N., Baba E., Murata K., Akazawa N., Suzuki Y., Satake H., Boku N., Hyodo I., Yoshimura K., Kawakami H., Hironaka S., Muro K.

    European Journal of Cancer 238   116688 2026年05月

    ISSN  09598049

    　概要を見る

    Background FOLFOXIRI plus bevacizumab improved efficacies and increased some adverse events in untreated metastatic colorectal cancer (mCRC), compared with the doublet plus bevacizumab. The clinical outcomes of ramucirumab (RAM) in combination with FOLFIRI or FOLFOXIRI as a first-line treatment are unknown. In this randomized phase II study (WJOG9216G), we compared the efficacy and safety of these regimens to determine which is more promising. Methods Patients with untreated mCRC were randomly assigned to the FOLFIRI-RAM or FOLFOXIRI-RAM arms. The primary endpoint was a confirmed objective response rate (ORR), and secondary endpoints included early tumor shrinkage (ETS), progression-free survival (PFS), overall survival (OS), and safety. Results In total, 122 patients were randomized. The confirmed ORR was 59.3% and 60.3% in the FOLFIRI-RAM and FOLFOXIRI-RAM arms, respectively (odds ratio 1.04; P = 0.91). With a median follow-up period of 42.1 and 40.4 months, PFS was comparable between the FOLFIRI-RAM and FOLFOXIRI-RAM arms (median, 11.5 and 10.5 months). ETS rate (71.2% and 52.4%) and OS (median, 32.6 and 28.2 months) were significantly better in the FOLFIRI-RAM arm than in the FOLFOXIRI-RAM arm. The major grade ≥ 3 adverse events in the FOLFIRI-RAM and FOLFOXIRI-RAM arms were neutropenia (44.1% and 72.6%), anorexia (3.4% and 14.5%), and febrile neutropenia (3.4% and 11.3%). Conclusions FOLFOXIRI plus RAM was not superior to FOLFIRI plus RAM in terms of efficacy, including ORR, in patients with untreated mCRC. Instead, first-line FOLFIRI plus RAM showed clinical efficacy and safety profiles comparable to those of doublet chemotherapy plus bevacizumab.

  • A pragmatic phase II trial evaluating treatment strategies using immune checkpoint inhibitors for metastatic esophageal cancer patients with severe dysphagia.

    Nagata Y, Arai H, Izawa N, Inagaki C, Sugaya A, Hirata K, Tsushima T, Moriwaki T, Masuishi T, Nagatani Y, Harada K, Taguri M, Sunakawa Y

    ESMO gastrointestinal oncology 11   100310 2026年03月

  • Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors

    Saito Y., Horie S., Kogure Y., Mizuno K., Ito Y., Mizukami Y., Kim H., Tamura Z., Koya J., Funakoshi T., Hirata K., Kataoka K.

    Nature Medicine 32 （ 2 ） 690 - 701 2026年02月

    ISSN  10788956

    　概要を見る

    Comprehensive genomic profiling (CGP) is crucial in precision oncology, yet its real-world utility remains unclear. Here we analyzed data from the Japanese nationwide Center for Cancer Genomics and Advanced Therapeutics database, including clinical and genetic data from 54,185 patients with advanced solid tumors (consisting of 81 common and rare tumor types) who received CGP with a targeted sequencing panel covering 324 genes as part of their clinical care. We assessed the prognostic value of CGP-guided clinical evidence-level classification, showing that alterations predicting response to Pharmaceuticals and Medical Devices Agency-approved or Food and Drug Administration-approved therapies and to therapies supported by well-powered studies with expert consensus are detected in 16.6% and 8.1% of patients, respectively, and are associated with better prognosis than those with lower clinical evidence levels. Only 8% of patients receive CGP-guided approved–experimental genomic biomarker-linked therapies, although the proportion has improved over time. Substantial differences were observed across tumor types, with the proportions exceeding 20% in thyroid and lung cancers but remaining below 2% in pancreatic and liver cancers. Tumor-agnostic biomarker analyses reveal that tumor mutational burden (TMB) ≥20 mutations per megabase predicts better outcome across tumor types, regardless of microsatellite instability status, in TMB-high patients receiving pembrolizumab. Conversely, extramammary Pagetʼs disease is exceptionally resistant to pembrolizumab. The large-scale nationwide database allows evaluating inter-tumor type differences and investigating evidence-scarce situations, delineating where CGP offers greater benefit. These real-world findings complement those from clinical trials and prospective sequencing projects regarding CGP, providing valuable information for individualized treatment.

  • Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan

    Hirata K., Hamamoto Y., Shoji H., Hara H., Kondoh C., Yasui H., Kajiwara T., Baba E., Ando T., Sugimoto N., Kawakami H., Katsuya H., Nagase M., Yamamoto Y., Yoshimura K., Ando M., Imamura C.K., Yamazaki K., Hironaka S., Muro K.

    Eclinicalmedicine 92   103768 2026年02月

    　概要を見る

    SummaryBackgroundGastric cancer (GC) with peritoneal dissemination remains a challenge with poor prognosis and limited treatment options. We aimed to compare solvent-based paclitaxel (sb-PTX) + ramucirumab (RAM) vs. nanoparticle-albumin-bound paclitaxel (nab-PTX) + RAM as second-line therapy for unresectable or recurrent GC with peritoneal dissemination.MethodsThis prospective, randomised, open-label, multicentre phase 2 trial was conducted at 58 centres within the West Japan Oncology Group (WJOG) in Japan. Eligible participants were patients with histologically-confirmed GC with peritoneal dissemination refractory or intolerant to first-line therapy. Patients were randomised 1:1 to receive sb-PTX + RAM or nab-PTX + RAM. Primary endpoint was overall survival (OS); key secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), safety, and protocol-specified biomarker analyses including the assessment of stromal caveolin-1 (Cav-1) expression by immunohistochemistry on archival tumour specimens. The data cutoff for the analysis presented herein was January 27, 2021. This trial was registered in the Japan Registry of Clinical Trials (jRCTs031180022).FindingsBetween Oct 1, 2018, and Jan 27, 2020, 105 patients were assigned to sb-PTX + RAM (n = 53) or nab-PTX + RAM (n = 52). Median follow-up was 18.1 months. Median OS was 8.1 months with sb-PTX + RAM and 7.2 months with nab-PTX + RAM (HR [nab-PTX + RAM vs. sb-PTX + RAM], 0.960; 95% CI, 0.621–1.484; P = 0.631). Median PFS was 5.1 vs. 3.9 months (HR [nab-PTX + RAM vs. sb-PTX + RAM], 0.965; 95% CI, 0.642–1.450; P = 0.893). ORR was 20.7% vs. 20.0% (P = 0.993), and DCR was 77.4% vs. 63.5% (P = 0.150), with sb-PTX + RAM and nab-PTX + RAM. Grade≥3 neuropathy occurred in 7.5% with sb-PTX + RAM and 17.6% with nab-PTX + RAM, and febrile neutropenia in 11.3% vs. 5.9%. In biomarker analysis, OS and PFS improved stepwise with increasing Cav-1 expression in patients receiving nab-PTX + RAM (P = 0.007, P = 0.012); no such association was observed with sb-PTX + RAM. Among patients with high stromal Cav-1 expression (IHC score 3+), nab-PTX + RAM showed some evidence of improved OS compared with sb-PTX + RAM (HR [nab-PTX + RAM vs. sb-PTX + RAM], 0.371; 95% CI, 0.130–1.060; P = 0.055). The interaction between Cav-1 expression and treatment arm showed a non-significant trend (HR for interaction, 0.364; 95% CI, 0.115–1.152; P = 0.086), consistent with this finding.InterpretationTreatment with nab-PTX + RAM did not meet the prespecified threshold (HR < 0.90) for promising efficacy in patients with GC and peritoneal dissemination. High stromal Cav-1 expression was associated with improved efficacy of nab-PTX + RAM. Future studies should prospectively validate the predictive value of stromal Cav-1 in patients receiving nab-PTX + RAM.FundingTaiho Pharmaceutical Co. Ltd.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

全件表示 >>

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • Vulnerable臨床病期IB-III食道扁平上皮癌患者に対するパクリタキセル併用放射線療法の第I相試験

    [国内会議] 

    2021年09月
    , 

    口頭発表（一般）

  • Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT.

    Kenro Hirata, Yasuo Hamamoto, Kenji Tsuchihashi, Chihiro Kondoh, Kentaro Yamazaki, Shuichi Hironaka, Masahiko Ando, Chiyo K Imamura, Kenichi Yoshimura, Kei Muro

    [国際会議]  The European Society for Medical Oncology Cancer Congress 2019, 

    2019年09月
    , 

    ポスター発表

  • 咽頭メラノーシスの視認は上気道消化管新生物予測に有用である

    平田 賢郎

    第15回日本臨床腫瘍学会学術集会, 

    2017年07月

  • Soft palatal melanosis as a predictor for neoplasia in the upper aerodigestive tract.

    平田 賢郎

    [国際会議]  American Society of Clinical Oncology 2017, 

    2017年06月

  • 上気道消化管新生物予測における咽頭メラノーシスの有用性の検討

    平田 賢郎

    アルコール医学生物学研究会, 

    2017年01月
    , 

    口頭発表（一般）

全件表示 >>

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • がん化学療法後に増悪した根治切除不能な進行・再発食道扁平上皮癌に対するNivolumab療法におけるバイオマーカー探索を含む前向き観察研究

    2021年
    -
    継続中

    共同研究契約,  研究代表者

  • 化学療法誘発性口腔粘膜炎における青黛軟膏の臨床開発

    2021年
    -
    継続中

    共同研究契約,  研究代表者

  • Vulnerable高齢食道扁平上皮癌患者に対する標準治療の確立

    2020年04月
    -
    2023年03月

    平田　賢郎, 補助金,  研究代表者

  • BRAF変異型Stage IV大腸癌に対するFOLFOXIRI+BEV療法の有効性に関する後方視的検討

    2020年04月
    -
    2021年03月

    その他,  研究代表者

  • オンライン診療を用いた緩和ケアの有用性に関する検討

    2020年04月
    -
    2021年03月

    共同研究契約,  研究代表者

全件表示 >>

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • 有吉・福岡賞

    2021年06月, 西日本がん研究機構（West Japan Oncology Group: WJOG）

    受賞区分： 出版社・新聞社・財団等の賞

  • J-HOPE award

    2019年03月, The University of Texas MD Anderson Cancer Center

    受賞区分： 出版社・新聞社・財団等の賞

  • 内科学教室同窓会　松木康夫賞

    2018年06月

  • 第８回 ICAT publication award

    2013年12月

  • 第７回 ICAT award 最優秀賞

    2012年12月

全件表示 >>

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 医学概論

    2026年度

  • 腫瘍学

    2026年度

  • がん専門看護実習

    2026年度

  • 内科学（消化器）講義

    2026年度

  • 臨床腫瘍学

    2026年度

全件表示 >>

このページの先頭へ▲
 

社会活動 【 表示 ／ 非表示 】

  • がん臨床研究指導者養成プロジェクト「虎の穴」ジュニアチューター

    2021年

  • 特定臨床研究への対応の実際

    西日本がん研究機構（WJOG）

    2020年05月

  • 大阪オンコロジーセミナー Meeting the Cancer Experts 2020 食道癌

    西日本がん研究機構（WJOG）

    2020年04月

  • 特定臨床研究への対応の実際

    西日本がん研究機構（WJOG）

    2019年

  • がん臨床研究指導者養成プロジェクト「虎の穴」ジュニアチューター

    2019年
このページの先頭へ▲

委員歴 【 表示 ／ 非表示 】

  • 2021年
    -
    継続中

    西日本がん研究機構（WJOG）消化器グループ　若手会FLAG 副代表, WJOG（西日本がん研究機構）

  • 2019年
    -
    継続中

    食道癌診療ガイドライン　システマティックレビュアー

  • 2019年
    -
    継続中

    JCOG（日本臨床腫瘍研究グループ）食道がんグループ　医学審査員

  • 2019年
    -
    継続中

    西日本がん研究機構（WJOG）臓器横断的ワーキンググループ　委員

  • 2019年
    -
    継続中

    胃癌治療ガイドライン システマティックレビュアー

全件表示 >>

このページの先頭へ▲